Natixis’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Natixis’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-215,731	Closed	-$12.7M	–	1277
2023 Q4	$12.7M	Buy	+215,731	New	+$12.1M	0.09%	184
2023 Q3	–	Sell	-3,500	Closed	-$126K	–	1158
2023 Q2	$126K	Sell	3,500 -28,209	-89%	-$1.16M	﹤0.01%	779
2023 Q1	$1.18M	Buy	+31,709	New	+$1.43M	0.01%	498
2022 Q4	–	Sell	-8,750	Closed	-$611K	–	1395
2022 Q3	$611K	Buy	+8,750	New	+$647K	﹤0.01%	859
2022 Q1	–	Sell	-13,450	Closed	-$1.97M	–	1367
2021 Q4	$1.97M	Buy	+13,450	New	+$2.09M	0.01%	777

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Natixis's MRTX Position: Q1 2024 in Review

Natixis sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 215,731 shares — an estimated $12.7M sold.

Natixis first reported a position in MRTX in Q4 2021 and held it in 5 quarters. The position peaked at $12.7M in Q4 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

Natixis reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Natixis sold 215,731 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $12.7M.
Natixis first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2021 and held it in 5 quarters.
Natixis's Mirati Therapeutics, Inc. Common Stock position peaked at $12.7M in Q4 2023.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Natixis's 13F filing for Q1 2024, filed 13 May 2024.